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Transforming growth factor beta (TGF-beta) is a potent immunosuppressant. The present study was 
conducted to develop a treatment strategy through adoptive transfer of tumor-reactive RNAi-induced 
TGF-beta-insensitive CD8+ T cells. BALB/c mice were primed with irradiated Renca cells. CD8+ T cells 
were isolated from the spleen of primed animals, expanded ex vivo and were rendered TGF-beta-
insensitive by infecting with a retrovirus containing shRNA to mouse TGF-beta type II receptor gene 
(MSCV-shRNA-T). Control CD8+ T cells consist of those infected with retroviruses containing shRNA to 
non specific gene (MSCV-shRNA-N) and naive CD8+ T cells. The effect of all groups of CD8+ T cells on 
Renca cells were analyzed by semi-quantitative RT-PCR, Western-blot, in vitro and in vivo assay. MSCV-
shRNA-T group of CD8+ T cells were resistant to the antiproliferative effect of exogenous TGF-beta, 
while control groups were not. Results of Western blot showed the Smad pathway was disrupted in 
MSCV-shRNA-T group, which confirmed the blockade of the signal transduction pathway. In vitro 
cytotoxic assay revealed that these tumor-reactive, TGF-beta-insensitive CD8+ T cells killed Renca cells 
specifically and strongly. Adoptive transfer of these MSCV-shRNA-T CD8+ T cells to BALB/c tumor-
bearing mice showed strong tumor-specific cytotoxic T lymphocyte responses and antitumor immunity 
against Renca renal cancer. Based on these results, we predict that adoptive transfer of tumor-reactive 
RNAi-induced TGF-beta-insensitive CD8+ T cells may be effective to renal cancer therapy. 
 






In recent years, immune elements as diverse as cyto-
kines, antibodies, vaccines and adoptive cell transfer 
regimens have emerged as promising cancer immuno-
therapy approaches with confirmed clinical efficacy 
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et al., 2003; Smyth et al., 2004). However, clinical trials 
aimed at harnessing and enhancing the endogenous 
immune system against most cancers generally resulted 
in a very low frequency of durable complete responses 
(Rosenberg et al., 1986, 2004; Figlin et al., 1999). 
Analysis of immune parameters in the majority of patients 
following immunotherapy has demonstrated the infer-
quent generation of endogenous T cells with activity 
against autologous tumors. The low success rate of 
immunotherapy may therefore be due to a deficiency of 
tumor-reactive T cells  in the  immune  repertoire  or  their  




Table 1. Synthesized shRNA sequences. 
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non responsive state, rendering them unable to become 
activated and expand in response to antigens. In addition, 
tumor-reactive T cells may not traffic effectively to tumors 
and may be inhibited by tumor-derived factors such as 
TGF-ß (Gorelik and Flavell, 2002). 
Transforming growth factor-beta (TGF-ß) is a 25-kDa 
multifunctional growth factor. It is implicated in many 
cellular processes, including growth and differentiation, 
angiogenesis, migration, deposition of extracellular matrix 
and immunosuppression (Massague, 1990; Moses et al., 
1990; Sporn and Roberts, 1991; Huang et al., 1995; 
Barrack, 1997; Gordon and Blobe, 2008). TGF-ß exerts 
these effects through binding to specific cell-surface 
receptors that act cooperatively. Three types of TGF-ß 
receptors have been identified: type I (TßR-I), type II 
(TßR-II) and type III (TßR-III). TßR-III is a proteoglycan. 
The biological function of TßR-III may involve 
presentation of TGF-ß to target cells, and it does not 
directly participate in signal transduction (Sun and Chen, 
1997). TßR-I and TßR-II, on the other hand, exhibit 
serine/threonine kinase activity in their intracellular 
domains (Wrana et al., 1992). The current understanding 
shows that TGF-ß first binds to TßR-II to form a complex. 
TßR-I is then recruited by this complex through phos-
phorylation and this leads to the phosphorylation of 
signaling pathway specific Smad-2 and Smad-3 molecules 
that oligomerize with the common mediator, Smad-4, 
resulting in their translocation to the nucleus (Massague, 
1998; Jayaraman and Massague, 2000). Therefore, the 
type II receptor provides a suitable target for disruption of 
the signaling pathway. Targeted disruption of the TGF-ß 
signaling pathway has been effectively achieved by 
restricting the expression of a dominant negative type II 
TGF-ß receptor in immune cells such as the bone 
marrow cells and CD8+ T cells (also called cytotoxic T 
Lymphocytes) or by silencing TßR-II via RNA interference 
in other tissue cells (Dudley et al., 2002; Shah et al., 
2002a,b; Nakamura et al., 2004; Jazag et al., 2005; 
Mizuguchi et al., 2005; Zhang et al., 2005, 2006).  
Historically, adoptive immunotherapy in cancer has 
shown promising clinical results by selection and ampli-
fication of autologous antigen-specific lymphocytes before 
reinjection into patients (Dudley et al., 2002; Mitchell et 
al., 2002; Yee et al., 2002). Although, renal carcinoma 
has no well-defined specific antigen, tumor-reactive CD8+ 
T cells can be isolated from hosts suffering from renal 
cancer. In addition, renal carcinoma cells produce a large 
amount of TGF-ß to inhibit the function of CD8+ T cells 
(Knoefel et al., 1997; Wunderlich et al., 1997, 1998; 
Kominsky et al., 2007), which leads to tumor escape from 
the host immunosurveillance and tumor progression.  
Considering this hypothesis, in the present study, we 
engineered tumor-reactive RNAi-induced TGF-ß-insensitive 
CD8+ T cells and evaluated their antitumor effect in vitro 
and in tumor-bearing mice. Our results indicated that 
these CD8+ T cells show strong tumor-specific cytotoxic T 
lymphocyte responses and antitumor immunity against 
Renca renal cancer, which provides proof that these 




MATERIALS AND METHODS 
 
Mice and Cells 
 
Eight-week-old BALB/c mice obtained from the Laboratory Animal 
Research Center of the Fourth Military Medical University were 
used according to the approved guidelines of the Fourth Military 
Medical University. The mouse renal carcinoma cell line, Renca 
cells (ATCC, USA), were maintained in complete medium (CM) 
consisting of RPMI-1640 with 10% heat-inactivated fetal bovine 




Construction of a retroviral vector for delivery of shRNA 
 
MSCV-TßRIIDN-IRES-GFP vector and pEGFP/U6 vector were 
provided by Prof. Chung Lee (Zhang et al., 2005) and Prof. Yang 
Shi (Sui et al., 2002), respectively. One pair of complementary 
oligonucleotides encoding mouse TGF-ß type II receptor gene 
(GenBank accession No. S69114) shRNA with a loop motif 
(Mizuguchi et al., 2005) and negative control shRNA targeting none 
specific gene (Table 1) were synthesized, annealed and ligated into 
the linearized pEGFP/U6 vector between the Apa I and EcoR I 
linker sequences (Figure 1A). After construction of pEGFP/U6-
shRNA, the U6-shRNA sequence was excised from it by BamH 
I/EcoR I digestion and inserted into the MSCV-TßRIIDN-IRES-GFP 
vector,   which   was   also  linearized  by  BamH I/EcoR I  digestion 






Figure 1. Construction of MSCV-shRNA retroviral vectors. A: shRNA was inserted into the pEGFP/U6 vector to 
construct the pEGFP/U6-shRNA vector; B: map of MSCV-TßRIIDN-IRES-GFP vector; C: U6-shRNA was excised 




(Figures 1B and C). These clones were designated as MSCV-
shRNA-T or MSCV-shRNA-N and screened by sequencing for 
correct orientation, sequence and insert number. 
 
 
Isolation and expansion of tumor-reactive CD8+ T cells 
 
BALB/c mice were primed with irradiated Renca cells (5 × 106/mice 
at 20,000 ci) by subcutaneous injection every 10 days for a total of 
3 inoculations. Two weeks following the last vaccination, splenic 
CD8+ T cells were isolated by using a murine T cell CD8+ subset 
column kit (R and D Systems, Minneapolis, MN) and expanded 
(105/ml) in the presence of Renca lysates (1 × 106) and irradiated 
autologous splenocytes (1 × 106/ml 3000 ci) in a medium containing 
RPMI-1640 with 10% FBS, IL-2 (50 U/ml), anti-CD3+ monoclonal 
antibody (30 ng/ml, R and D), HEPE (25 mM), L-glutamine (4 mM), 
and 2-ME (25 mM). The medium was changed every 3 days. 
 
 
Production of infectious MSCV-shRNA retrovirus 
 
Pantropic GP293 retroviral packaging cells (Clontech, San Diego, 
CA) were seeded at a density of 2.5 × 106 cells in collagen-I-coated 
T-25 flasks (BIOCOAT, BD Biosciences) 24 h before plasmid 
transfection in antibiotic-free 10% DMEM, such that the cells were 
70 - 90% confluent at the time of transfection. At this point, the cells 
were rinsed with PBS to remove residual serum. A mixture of 2 g 
retroviral plasmid and 2 g VSV-G envelope plasmid was co-
transfected in serum-free DMEM using Lipofectamine-Plus (Invitrogen, 
USA) according to the manufacturer’s protocols with some 
modifications. Briefly, cells were transfected for 12 h followed by the 
addition of an equivalent volume of 10% DMEM and reincubation 
for an additional 12 h. After the reincubation, the supe-rnatant was 
aspirated, the cells were rinsed gently in PBS, and 3 ml of fresh 
10% DMEM was added into each flask. Virus-containing super-
natant was collected 24 h later and used to infect the target cells or 
stored at -80°C. 
 
 
Infection of CD8+ T cells with retrovirus containing shRNA-T or 
shRNA-N 
 
CD8+ T cells were infected with MSCV-shRNA-T and MSCV-
shRNA-N. The infection efficiency was 93.9% for the MSCV-
shRNA-T vector and 92.8% for the MSCV-shRNA-N control vector 
(Figure 2A). Three types of CD8+ T cells were established in each 
time group. The first type was tumor-reactive RNAi-induced TGF-ß-
insensitive CD8+ T cells (tumor-reactive CD8+ T cells infected with 
the MSCV-shRNA-T virus). The second type was tumor-reactive 
CD8+ T cells infected with the MSCV-shRNA-N virus. The third type 
was   naive  CD8+  T  cells,  which  were  freshly  isolated  from  the 






Figure 2. Efficient Inhibition of TGF-ß Type II Receptor by MSCV-shRNA-T Retrovirus. A: Most CD8+ T cells appeared 
green under a fluorescent microscope, which indicated that the efficiency of the infection was high and the reconstruction 
of MSCV-shRNAs was successful, B and C: compared with control groups, the level of TßRII mRNA was down-regulated 
in the MSCV-shRNA-T-infected group (P < 0.05), Correspondingly, D and E: show that the protein level of TßRII in the 
MSCV-shRNA-T group was also reduced(P < 0.05). There were 3 samples in every group when the semi-quantitative 
RT-PCR and Western-blot were performed. 




spleen of naive donor animals without any treatment. 
 
 
Reverse transcription-PCR analysis for TGF-ß type II receptor 
mRNA 
 
Total RNA of CD8+ T cells infected with two shRNA expression 
vectors after 48 h was extracted by using Trizol reagent according 
to the manufacturer’s protocol (Invitrogen) and quantified at a 1/100 
dilution of the RNA on a spectrophotometer prior to use. cDNA 
synthesis was performed at 50°C for 30 min (SuperScript™ 
preamplification system, Invitrogen) and the PCR conditions were 
as follows: 1 cycle of pre-denaturation (94°C, 5 min), 30 cycles of 
denaturation (94°C, 15 s), annealing (52°C, 30 s), extension (72°C, 
40 s), and 1 cycle of final extension (72°C, 7 min). Glyceraldehyde-
3-phosphate-dehydrogenase (GAPDH) was used as an internal 
control. The primers used were as follows: TßRII-forward, 5'-
ttcgccgaggtctacaag-3'; TßRII-reverse, 5'-gacttgacctgttgcctgt-3'. 
GAPDH-forward, 5'-tcggagtcaacggatttggtcgta-3'; GAPDH-reverse, 
5'-agccttctccatggtggtgaaga-3'. Then, quantitate mRNA levels of 
TßRII and GAPDH were analyzed. PCR products were separated 
on a 1% agarose gel in 0.5% TBE. A semi-quantitative PCR 
method was used to determine the percentage of inhibition of 
TßRII, along with the use of the National Institutes of Health (NIH) 
ImageJ v1.34 software to scan the PCR amplified products directly 
from the images of the agarose gel bands. Thus, a relative 
quantification of the TßRII products was obtained in comparison 
with the expression level of TßRII in nave CD8+ T cells. The 
relative values were expressed in pixels as integrated densities. 
 
 
Western blot analysis for TßRII protein and SMAD-2 
phosphorylation 
 
After 48 h of infection, CD8+ T cells were treated with 10 ng/ml of 
TGF-ß1 for 16 h. Then, CD8+ T cells were harvested and total 
proteins were extracted by adding an RIPA buffer (Zhang et al., 
2005) to cell pellets. Approximately 30 µg of total protein extract 
was subjected to electrophoresis (Novex/10% acrylamide gel) and 
blotted onto a polyvinylidene difluoride membrane. Blots were 
probed using anti-TßRII (Jackson ImmunoResearch), anti-Smad2 
(Upstate Biotechnology, Lake Placid, NY), antiphospho-Smad2 
(Upstate Biotechnology) or anti-GAPDH (Chemicon, Temecula, CA) 
mAb. Proteins of interest were detected using an enhanced chemi-
luminescence system (ECL Kit, Pierce) followed by exposure to a 
Kodak X-OMAT AR film. The National Institutes of Health (NIH) 
ImageJ v1.34 software was used to scan the bands. 
 
 
Thymidine incorporation assay 
 
CD8+ T cells (3 × 104 cells/24-well) were treated with or without 10 
ng/ml murine TGF-ß1 (R and D Systems, USA) for 16 h. A medium 
containing [3H]-thymidine (0.5 µCi/ml; Amersham Pharmacia 
Biotech) was introduced and cells were cultured for an additional 5 
h. The experiment was terminated by washing with warm serum-
free medium and the samples were harvested for determining the 
radioactivity. The antiproliferative effect of TGF-ß1 on these CD8+ T 
cells was expressed as follows: 100 × (R1 – R2)/R1, where R1 
represents the count of radioactivity in groups without TGF-ß1 and 
R2, that with TGF-ß1. 
 
 
In vitro cytotoxic assay 
 
The above three types of CD8+ T cells were used as effector cells 
against 51Cr-Renca cells or 51Cr-B16-F10 cells (mouse melanoma 





assay was performed as described elsewhere (Shah et al., 2002b). 
Briefly, target cells were labeled with 0.1 mCi of 51Cr per 106 cells 
for 4 h at 37°C, followed by 5 washes in PBS(–) and they were 
seeded in 96 well U-bottom plates (5,000 cells/well). CD8+ T-cells 
were added at different effector/target ratios (1:1 to 100:1) for 5 h. 
The supernatants were collected and the released radioactivity was 
measured using a gamma counter. The percentage of specific lysis 
was determined as follows: 100 × ([Experimental 51Cr Release – 
Spontaneous 51Cr Release]/ [Maximum 51Cr Release – Sponta-
neous 51Cr Release]). The maximum release was determined by 
adding 2% sodium dodecyl sulfate to the target cells. 
 
 
In vivo anti-tumor assay 
 
Renca cells (3 × 105 cells per mouse) were subcutaneously (s.c.) 
implanted into BALB/c mice (n = 10/group) in the right flank (day 0). 
Tumors that were approximately 2 - 3 mm in diameter developed 
ten days later. After the tumors developed, the adoptive transfer of 
CD8+ T cells (2 × 106) through the tail vein was performed on either 
day 2, 9, or 20. Tumor growth and mouse survival were monitored 
weekly post-inoculation. Forty days after adoptive transfer, all 
animals were sacrificed, although, some animals died earlier due to 
poor health conditions. Splenic CD8+ T cells were isolated and the 
percentage of GFP-positive CD8+ T cells in each spleen was 
calculated following analysis by flow cytometry. All the animals’ 
subcutaneous tumors were excised for observation. The diameters 
of the tumors were measured using a digital caliper and the tumor 
volumes were calculated by the formula: v = a × b2/2 mm3, where a 





Statistical significance was determined by unpaired Student’s t-test, 
ANOVA and Mantel-Haenszel log-rank test using commercially 
available software (Stat-200, BIOSOFT, Cambridge, UK). P < 0.05 





Efficient inhibition of TGF-ß Type II receptor by 
MSCV-shRNA-T retrovirus 
 
Tumor-reactive CD8+ T cells were infected with MSCV-
shRNA-T or MSCV-shRNA-N retrovirus. Twenty-four 
hours after infection, we observed the CD8+ T cells using 
a Nikon TE2000-U fluorescent microscope (Nikon Corp., 
Tokyo, Japan). Most cells were green (Figure 2A), which 
indicated that insertion of the U6 promoter has no 
noticeable effects on virus packaging or infectivity. Forty-
eight hours after infection, the infected or nave CD8+ T 
cells were harvested for RT-PCR and Western blot 
analysis of TßRII. Compared with control groups, the 
level of TßRII mRNA was down-regulated in the MSCV-
shRNA-T-infected group (Figures 2B and C). Corres-
pondingly, the results of Western blot analysis showed 
that the protein level of TßRII in MSCV-shRNA-T group 
was also reduced (Figures 2D and E). These results 
revealed that the MSCV-shRNA-T retrovirus efficiently 






Functional status of TGF-ß signaling in RNAi-induced 
TGF-ß-insensitive CD8+ T cells 
 
Under normal conditions, CD8+ T cells express a high 
level of TßRII and they are highly sensitive to TGF-ß. 
When CD8+ T cells were infected with the retrovirus 
containing shRNA-T, they became insensitive to TGF-ß, 
as shown by the following tests. In our study, all three 
types of CD8+ T cells were treated with or without 10 
ng/ml TGF-ß1. Western blot analysis demonstrated the 
presence of Smad-2 in all the CD8+ T cell groups. 
However, phosphorylated Smad-2 was only detected in 
MSCV-shRNA-N-infected CD8+ T cells and nave CD8+ T 
cells treated with TGF-ß1. In contrast, phosphorylated 
Smad-2 was not detected in MSCV-shRNA-T-infected 
CD8+ T cells after the addition of TGF-ß1, confirming that 
TGF-ß signal transduction was blocked by the presence 
of shRNA to TßRII (Figure 3A). 
To confirm whether the MSCV-shRNA-T-infected CD8+ 
T cells could overcome the antiproliferative effects of 
TGF-ß1, thymidine incorporation assay was performed. 
TGF-ß1 showed a dramatic antiproliferative effect on the 
established MSCV-shRNA-N-infected CD8+ T cells and 
naive CD8+ T cells, inhibiting uptake by a mean of 62.5% 
(range, 47 - 80%) and 65.5% (range, 49 - 84%), respec-
tively (Figure 3B). On the other hand, the mean inhibition 
of thymidine uptake by MSCV-shRNA-T-infected CD8+ T 
cells was 15% (range, 0 - 28%) (Figure 3B). The 
resistance to antiproliferative effects in MSCV-shRNA-T-
infected CD8+ T cells was statistically significant when 
compared with that in MSCV-shRNA-T-infected CD8+ T 
cells (P = 0.02) or naive CD8+ T cells (P = 0.02). 
 
 
In vitro anti-tumor activity of tumor-reactive RNAi-
induced TGF-ß-insensitive CD8+ T cells 
 
Tumor-reactive RNAi induced TGF-ß-insensitive CD8+ T 
cells exhibited potent specific lysis against Renca cells 
(Figure 3C). These cells showed a 4 fold greater tumor-
killing activity than their TGF-ß-sensitive counterparts and 
20 fold greater activities over that of naive CD8+ T cells. 
Both the TGF-ß-sensitive and TGF-ß-insensitive tumor-
reactive CD8+ T cells exhibited no apparent lysis when 
incubated with an irrelevant cell line, mouse B16-F10 
melanoma cells (Figure 3D). 
 
 
Increased survival and suppressed growth of renca 
renal cancer in RNAi-induced TGF-ß-insensitive CD8+ 
T cells adoptive transferred mice 
 
In the absence of any intervention, on day 10, following 
the s.c. injection of tumor cells, the subcutaneous tumor 
burden was evident. Animals that received an adoptive 
transfer of tumor-reactive RNAi induced TGF-ß-insensitive 
CD8+ T cells showed  the least  degree  of  tumor  burden 




(Figures 4A and B). There was no evidence of 
subcutaneous tumors in the group of mice that received 
an adoptive transfer 2 days after the formation of tumor 
burden. Four animals out of ten in the 9 day group were 
found to have small subcutaneous tumors at the time of 
sacrifice. Two animals out of 10 in the 20 day group had 
to be sacrificed earlier due to poor health conditions and 
they were found to have obvious subcutaneous tumors. 
All the remaining 8 animals in the 20 day group were 
found to have a tumor burden with the volume range of 
183.5-387.5 mm3. Animals that received adoptive transfer 
of MSCV-shRNA-N-infected CD8+ T cells showed an 
intermediate degree of tumor burden, while those that 
received an adoptive transfer of naive CD8+ T cells were 
ineffective in inhibiting tumor progression. Analysis of 
Kaplan-Meier survival cure showed highly significant 
differences among the three treatment groups (Figure 
4C). 
Furthermore, we detected the fraction of GFP-positive 
CD8+ T cells in the spleens of tumor-burdened mice. After 
sacrifice of the tumor-burdened mice, the CD8+ T cells 
were isolated for flow cytometry analysis. Adoptively 
transferred tumor-reactive RNAi-induced TGF-ß-insensitive 
CD8+ T cells were detected with a percentage of 2.05 ± 
0.31%, suggesting that these CD8+ T cells were able to 
persist in recipient hosts at least at the time of sacrifice, 
which occurred 40 days after the initial adoptive transfer. 
In contrast, in animals that received the MSCV-shRNA-N 
infected tumor-reactive CD8+ T cells or naive CD8+ T 
cells, only occasional CD8+ T cells were detected with a 
percentage of 0.13 ± 0.02% (Figure 4D). These results 
indicated that RNAi-induced blockade of TGF-ß signaling 
in tumor-reactive CD8+ T cells efficiently activated the 





Secretion of TGF-ß is a strategy commonly used by 
tumors to thwart cellular immune responses. The secretion 
may interfere with several CD8+ T cell functions, including 
down-regulation of cell surface MHC antigens or 
molecules, as well the inhibition of CD8+ T cell 
proliferation (Gorelik and Flavell, 2002). This may 
severely affect the tumor-killing activity of CD8+ T cells. 
Tumor cells themselves may be sensitive to TGF-ß-
induced differentiation and apoptosis but can avoid this if 
they also possess mutant receptors for the cytokine 
(Wunderlich et al., 1997, 1998; Engel et al., 1999; 
Kominsky et al., 2007). We now show that such mutants 
can be adapted for the protection of CD8+ T cells. RNAi 
to TGF-ß type II receptor may provide an approach to 
protect CD8+ T cells from the inhibitory effects of TGF-ß 
signaling (Nakamura et al., 2004; Jazag et al., 2005; 
Mizuguchi et al., 2005). This tumor-derived defense may 
have clinical values if TGF-ß-insensitive CD8+ T cells 
were used for the treatment  of  TGF-ß-secreting  tumors,  






Figure 3. Western blot analysis for phosphorylated Smad2, thymidine incorporation assay for the proliferation of CD8+ T Cells and in 
vitro cytotoxicity assay. A: All three types of CD8+ T cells were treated with or without 10 ng/ml TGF-ß1. The presence or absence of 
Smad2 (S2) and phosphorylated Smad2 (P-S2) was detected by Western blot using anti-Smad2 and antiphospho-Smad2 antibodies, 
respectively. In contrast to the fact that phosphorylated Smad-2 was detected in the other two groups with TGF-ß1, we did not detect P-
S2 in MSCV-shRNA-T-infected CD8+ T cells after the addition of TGF-ß1. This confirmed that TGF-ß signal transduction was blocked 
by the presence of the shRNA to TßRII; B: proliferative responses of CD8+ T cells were measured with the 3[H] thymidine. TGF-ß1 
showed a dramatic antiproliferative effect on the established MSCV-shRNA-N-infected CD8+ T cells and naive CD8+ T cells, whereas 
the mean inhibition of thymidine uptake by MSCV-shRNA-T-infected CD8+ T cells was lower. It was statistically significant between the 
MSCV-shRNA-T-infected group and the other two control groups (P < 0.05). In Vitro cytotoxicity assay was also performed; C: Renca 
mouse-derived renal cancer cells were used as the targets. Tumor-reactive RNAi induced TGF-ß-insensitive CD8+ T cells exhibited 
potent specific lysis against Renca cells compared with other two groups (P < 0.05); D: B16-F10 mouse-derived melanoma cells were 
used as targets. Both the TGF-ß-sensitive and TGF-ß-insensitive tumor-reactive CD8+ T cells exhibited no apparent lysis (P > 0.05). 
Each point represents the mean of triplicate cultures. For thymidine incorporation assay, we had taken 3 wells of cultured cells as 
targets in every group. For in vitro cytotoxicity assay, at each effector/target ratio, 5 wells of cultured cells were targeted in every group. 




including renal cancer (Knoefel et al., 1997; Wunderlich 
et al., 1997, 1998). Immunotherapy using adoptive transfer 
of immune cells is a promising approach for treating 
cancer patients. However, currently available therapies 
have not achieved a significant number of complete 
responders. A success-sful adoptive therapy for cancer 
should be the development of robust effector cells with 
specific anti-tumor efficacy. At the same time, the treatment 






Figure 4. In vivo anti-tumor assays. Recipient mice received a single subcutaneous injection of Renca cells (5 × 105). At 2, 9, or 20 
days following the tumor-burden formation, the adoptive transfer of CD8+ T cells was carried out. Total animals (n = 10) were sacrificed 
40 days after the adoptive transfer or sooner due to poor health conditions. A: Representative subcutaneous tumors from tumor-bearing 
mice 40 days after the administration of adoptive transfer; B: volume of tumors. MSCV-shRNA-T-treated mice in the 20-day group were 
found to have the smallest and lightest tumor burden, P < 0.05; C: Survival was defined as ‘still be alive’. Kaplan-Meier survival curve of 
tumor-bearing mice received adoptive transfer of nave CD8+ T cells, MSCV-shRNA-N-infected CD8+, and MSCV-shRNA-T-infected 
CD8+ T cells. P < 0.05 according to the log-rank test for the MSCV-shRNA-T group versus the naive or MSCV-shRNA-N group. B and C 
show the results for the 20-day group; D: %GFP-positive CD8+ T cells in the spleen of tumor-bearing animals (20-day group). A total of 
2 × 106 CD8+ T cells were tail-vein-injected into tumor-bearing BALB/c mice. %GFP-positive CD8+ T cells in the spleen was analyzed by 
fluorescent-activated cell sorting. Adoptively transferred tumor-reactive RNAi-induced TGF-ß-insensitive CD8+ T cells were detected 
with a percentage of 2.05 ± 0.31%, while in animals that received the MSCV-shRNA-N-infected tumor-reactive CD8+ T cells or nave 




should overcome the tumor-derived immunosuppressive 
effect. 
In our study, we found that the adoptive transfer of 
tumor-reactive RNAi-induced TGF-ß-insensitive CD8+ T 
cells to BALB/c tumor-bearing mice could obviously 
increase the survival and suppress the growth of renca 
renal cancer. Furthermore, complete tumor regression 
occurred in the 2 day group of tumor-bearing mice. In 
contrast, the MSCV-shRNA-N-infected CD8+ T cells or 
the nave CD8+ T cells did not show such therapeutic 
effects. We also found GFP-positive CD8+ T cells isolated in 
sacrificed tumor-burdened mice. These results suggest 
that these tumor-reactive RNAi-induced TGF-ß-insensitive 
CD8+ T cells may overcome the tumor-derived immuno-
suppressive effect to reduce tumor burden effectively and 
may be maintained in tumor-burdened mice for at least 
40 days. 
Inhibition of the TGF-ß signal transduction pathway in 
the MSCV-shRNA-T infected CD8+ T cells was demon-
strated by an absence of detectable phosphorylated 
Smad-2, as indicated by the Western blot, in the presence 
of TGF-ß1 and a resistance to the antiproliferative effects  




of TGF-ß1, as found in 3[H]thymidine incorporation 
assays. In the present study, the complete absence of 
phosphorylated Smad-2 in the MSCV-shRNA-T infected 
CD8+ T cells and the 15% mean inhibition of thymidine 
uptake by these cells suggests the efficient blockade of 
the TGF-ß signaling pathway. 
In our study, we chose mouse renca renal cancer to 
investigate this strategy because the tumor cells repre-
sent an aggressive line of malignant cells that secrete 
large amounts of TGF-ß (Knoefel et al., 1997; Wunderlich 
et al., 1997, 1998). The results of in vitro cytotoxic assay 
demonstrated that tumor-reactive RNAi-induced TGF-ß-
insensitive CD8+ T cells represent potent specific lysis 
against renca cells (Figure 3C). These cells showed a 4 
fold greater tumor-killing activity than their TGF-ß-
sensitive counterparts and a 20 fold greater activity over 
nave CD8+ T cells. Both TGF-ß-sensitive and TGF-ß-
insensitive tumor-reactive CD8+ T cells showed no 
apparent lysis when incubated with an irrelevant cell line, 
mouse B16-F10 melanoma cells (Figure 3D). Based on 
these results, we concluded that tumor-reactive RNAi-
induced TGF-ß-insensitive CD8+ T cells showed strong 
tumor-specific cytotoxic T lymphocyte responses and 
antitumor immunity against renca renal cancer. To our 
knowledge, the present study is the first report in which 
murine stem cell virus (MSCV)-induced RNAi to TGF-ß 
type II receptor was applied to evaluate adoptive transfer 
immunotherapy of tumor-reactive RNAi-induced TGF-ß-
insensitive CD8+ T cells to renca renal cancer. Though 
the infection efficacy of MSCV retrovirus in vitro was 
satisfied, the infection efficacy in vivo is still unknown. We 
still need more investigations to show the infection 
efficacy of MSCV retrovirus in vivo. Our present results 
showed that adoptive transfer with tumor-reactive RNAi-
induced TGF-ß-insensitive CD8+ T cells to tumor-bearing 
mice was able to increase survival and suppress growth 
of autologous tumors. These tumor-reactive RNAi-
induced TGF-ß-insensitive CD8+ T cells have two exclusive 
characteristics. One is that they are specifically reactive 
against tumor tissues and the other is that they are 
insensitive to TGF-ß. These two properties endowed 
these CD8+ T cells with the ability of strong tumor-specific 
cytotoxic T lymphocyte responses and antitumor 
immunity against tumor cells. We found no evidence that 
even long-term expression of the shRNA to TßRII had 
any deleterious effects on the CD8+ T cells. In particular, 
their phenotype and cytotoxic specificity were unmodified. 
Our preliminary observations seem to suggest an 
apparent absence of the development of autoimmune 
disease in these animals. Further studies are required to 
verify this conjecture. 
In summary, this present study demonstrated a potential 
therapeutic approach to eliminate immunosup-pressive 
tumor-derived factors and improve the effectiveness of 
CD8+ T cells. Based on these results, we predict that 
adoptive transfer of tumor-reactive RNAi-induced TGF-ß-
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CM, Complete medium; CTL, cytotoxic thymus 
lymphocyte; FBS, fetal bovine serum; GFP, green 
fluorescent protein; TGF-ß, transforming growth factor 
beta; Renca, mouse-derived renal cancer; TßRI, type I 
TGF-ß receptor; TßRII, type II TGF-ß receptor; TßRIII, 
type III TGF-ß receptor; RNAi, RNA interference; 
GAPDH, glyceraldehyde-3-phosphate-dehydrogenase; 
MHC, major histocompatibility complex; MSCV, murine 
stem cell virus; DMEM, dulbecco's modification of eagle's 
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